<DOC>
	<DOCNO>NCT00464672</DOCNO>
	<brief_summary>This protocol design evaluate safety , clinical tolerability immunogenicity 2007 southern hemisphere formulation Novartis conventional influenza vaccine license EU many worldwide country , accord US FDA Draft Guidance Industry `` Clinical data need support licensure trivalent inactivate influenza vaccine '' , issue March 2006 , evaluate safety , clinical tolerability immunogenicity 2007 southern hemisphere formulation Novartis conventional influenza vaccine already license US . The purpose control arm primarily provide comparative assessment safety , immunogenicity effectiveness .</brief_summary>
	<brief_title>Safety , Immunogenicity Two Influenza Vaccines Healthy Subjects 3 64 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject 3 64 year age Receipt investigational product within 3 month vacine within 1 month ; Allergy egg , egg product , vaccine component ; Laboratory confirm influenza disease within 6 month ; Have previously receive influenza vaccination ( 3 8 year ) ;</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Influenza , Egg-Derived , Healthy Children , Healthy Adolescents , Healthy Adults , Safety , Immunogenicity , Trivalent , Inactivated , Vaccination</keyword>
</DOC>